Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event rather than comprehensive financial performance.
Material Changes
The filing reports an increase in the shareholding interest of Dr. M. M. Slaoui. This increase resulted from the re-investment of a dividend paid to shareholders on October 7, 2010. The transaction involved the purchase of 282 Ordinary shares at a price of £13.15 per share on October 13, 2010.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a director's transaction in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: October 13, 2010
- Shareholder: Dr. M. M. Slaoui
- Shares Acquired: 282 Ordinary shares
- Price per Share: £13.15
- Source of Funds: Re-investment of dividend paid on October 7, 2010
- Reporting Date: October 14, 2010